Status:
COMPLETED
Odiparcil For The Prevention Of Venous Thromboembolism
Lead Sponsor:
GlaxoSmithKline
Conditions:
Deep Vein Thrombosis
Fibrillation, Atrial
Eligibility:
All Genders
35+ years
Phase:
PHASE2
Brief Summary
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
Eligibility Criteria
Inclusion
- Women must be unable to have children.
- Will have a total knee replacement.
Exclusion
- Allergic to any X-ray dye.
- Allergies or reactions to warfarin or coumadin.
- Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT).
- On anticoagulation therapy.
- Renal impairment.
- Participated in any clinical trial in the past 30 days.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
961 Patients enrolled
Trial Details
Trial ID
NCT00244725
Start Date
September 1 2005
End Date
September 1 2006
Last Update
May 2 2017
Active Locations (101)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35209
2
GSK Investigational Site
Mobile, Alabama, United States, 36608
3
GSK Investigational Site
Phoenix, Arizona, United States, 85023
4
GSK Investigational Site
Little Rock, Arkansas, United States, 72205